Brandon Yaras - 01 Oct 2026 Form 4 Insider Report for aTYR PHARMA INC (ATYR)

Reporting relationship: Chief Financial Officer
Issuer ticker: ATYR
Reported as of: 01 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Oct 2026, 16:03:45 UTC
Source filing: View source filing
Reporting owner signature: /s/ Brandon Yaras

Key filing fact

Brandon Yaras filed Form 4 for aTYR PHARMA INC (ATYR) on 01 Oct 2026.

Key facts

This page summarizes Brandon Yaras's Form 4 filing for aTYR PHARMA INC (ATYR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Oct 2026, 16:03.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002156611 Primary reporting owner

Yaras Brandon

Relationship: Chief Financial Officer
Address: 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO
Signature: /s/ Brandon Yaras
Signature date: 01 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATYR transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +410,000
Change %
Price: $0.000000^*
Shares after: 410,000
Date: 01 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 410,000
Exercise price: $0.3000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning November 1, 2026, such that this option will be fully exercisable on November 1, 2030. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.